GI in Pregnancy: Pregnancy-Specific Liver Diseases

0:00Welcome to Board Pearls. This is episode three of six of the GI in Pregnancy chapter, in the Special Populations and Acute or Supportive Care module. In this episode we cover the pregnancy-specific liver diseases: intrahepatic cholestasis of pregnancy with elevated bile acids and ursodeoxycholic acid, the preeclampsia, HELLP, and AFLP spectrum where delivery is the definitive treatment, and hepatic rupture as the catastrophic complication.

0:28Liver disease in pregnancy splits cleanly into two halves, and the split is the way to think about every stem you will see. On one side are the pregnancy-specific syndromes. They exist only because pregnancy is occurring, they resolve with delivery, and delivery is the treatment. On the other side is incidental hepatic disease, viral hepatitis with drugs that are safe through pregnancy, and pre-existing liver disease where pregnancy changes the management. This episode covers the pregnancy-specific syndromes, because the recognition pattern and the trigger for delivery is what the boards test hardest.

1:02Begin with intrahepatic cholestasis of pregnancy, the most common pregnancy-specific liver disease. US prevalence is roughly one to two percent. The Araucanian Indian population in Chile runs as high as twenty-seven percent, which is a clue that the susceptibility is genetic. The susceptibility genes encode the canalicular bile acid transporters. ABCB11 encodes BSEP, the bile salt export pump. ABCB4 encodes MDR3, the phospholipid transporter. ATP8B1 encodes FIC1, an aminophospholipid translocase. Variants in these genes reduce the capacity of those transporters to keep up with the bile acid load that estrogen and progesterone impose in late pregnancy. The hormonal milieu pushes a system that is already running near its limit past its limit, and bile acids accumulate. Severe ICP, recurrent ICP, or early-onset ICP should prompt genetic testing, because some of these patients turn out to carry benign recurrent intrahepatic cholestasis or PFIC variants that change long-term hepatobiliary care.

2:11There is one other susceptibility worth knowing. Hepatitis C raises ICP risk about twentyfold, because HCV further impairs bile acid transporter function. So HCV serology belongs in the ICP workup.

2:25The presentation is in the second or third trimester, typically twenty-five to thirty-two weeks, with pruritus that is worse at night and predominantly involves the palms and soles. The pruritus is often the only symptom. It can precede the laboratory abnormalities, which means if a patient has classic palmoplantar nocturnal itch and normal initial labs, the right move is to recheck. Jaundice happens in only ten to twenty-five percent of cases, and it always follows the pruritus.

2:53The diagnostic threshold is total bile acids above ten micromol per liter. Severe disease is bile acids at or above one hundred. The biochemical signature that discriminates ICP from obstructive cholestasis is GGT. Alkaline phosphatase is up. 5'-nucleotidase is up. AST and ALT can rise, sometimes briskly, but they rarely cross a thousand. GGT, however, is characteristically normal. The reason is mechanistic. The BSEP, MDR3, or FIC1 defect impairs canalicular bile acid handling without producing the ductal injury that drives GGT release. Obstructive cholestasis injures the ducts and lifts GGT. ICP impairs the transporter and leaves GGT alone. That is the discriminator. A stem that gives you bile acids in the eighties, AST in the hundreds, ALP up, and a normal GGT is ICP. The same labs with a high GGT is biliary obstruction, and the next step is ultrasound and MRCP, not UDCA. Right upper quadrant ultrasound to exclude obstructive disease still belongs in the ICP workup before you finalize the diagnosis.

4:10The treatment is ursodeoxycholic acid, ten to fifteen milligrams per kilogram per day, titrated to symptoms. Roughly five hundred to two thousand milligrams a day in practice. The mechanism is direct. UDCA is hydrophilic. It competes with hydrophobic toxic bile acids in the bile pool, displaces them, and improves canalicular transport. It also crosses the placenta, where it protects fetal cardiomyocytes from bile acid-induced arrhythmia. About three quarters of patients respond with reduced bile acids and reduced pruritus.

4:44There is an important caveat. A large randomized trial did not show fetal outcome improvement with UDCA versus placebo, which raised real questions about routine use. UDCA remains recommended anyway, because it produces clear maternal symptomatic and biochemical improvement, and subsequent meta-analyses suggest fetal benefit at the higher bile acid levels where absolute risk is highest. The posture is continued use, with that trial informing nuance rather than abandonment of therapy.

5:15Vitamin K is given around delivery, because cholestasis impairs fat-soluble vitamin absorption and raises peripartum bleeding risk. Cholestyramine is the alternative for patients who cannot tolerate UDCA, but it is poorly tolerated itself and worsens fat-soluble vitamin malabsorption. So UDCA is the answer, and cholestyramine is the second-line.

5:36Now the part of ICP that organizes everything else. Why is the disease taken seriously. Fetal mortality. Bile acids cross the placenta and bind fetal cardiomyocyte muscarinic and bile acid receptors, producing arrhythmia, while hydrophobic toxic bile acids deposit in fetal tissues. A large individual-patient-data meta-analysis stratified fetal risk into three tiers based on maternal total bile acid level. Below forty, fetal mortality is close to baseline. Forty to ninety-nine, it is modestly elevated. At or above one hundred, the curve inflects sharply. Stillbirth risk in the severe group is approximately three point four percent versus zero point one three percent baseline.

6:21That stillbirth inflection is what drives delivery timing. The principle is that you induce when the fetal mortality risk of staying in utero exceeds the fetal lung maturity risk of coming out. Below forty, mortality is at baseline, so you deliver at thirty-nine weeks as you would in any uncomplicated pregnancy. Forty to ninety-nine, you deliver between thirty-six and thirty-nine weeks, individualized by symptom control and obstetric factors. At or above one hundred, you deliver at thirty-six to thirty-seven weeks, because the steep stillbirth risk outweighs the modest gain in fetal lung maturity from waiting another two weeks. The whole stratification answers one question. Where on the curve does the patient sit, and where is the curve inflecting.

7:09ICP resolves within one to two weeks postpartum. Pruritus goes away. Bile acids normalize. But recurrence in the next pregnancy is high, sixty to ninety percent, and ICP also recurs with combined hormonal contraceptive use, because exogenous estrogen does the same thing as endogenous estrogen to the transporters. So combined hormonal contraception is generally avoided in a patient with prior ICP. Progestin-only options or non-hormonal options are preferred. Long term, these women have elevated risk of HCV, nonalcoholic cirrhosis, gallstones, and nonalcoholic pancreatitis. Long-term follow-up matters.

7:50That is ICP. Now to the third-trimester emergencies, which share the feature that delivery is the only definitive treatment, and which test as a recognition problem in which two distinct mechanisms produce overlapping clinical presentations.

8:04Preeclampsia is hypertension at or above one forty over ninety with proteinuria or end-organ dysfunction after twenty weeks of gestation. It affects three to ten percent of pregnancies. Severe preeclampsia is BP at or above one sixty over one ten, or any end-organ dysfunction. Oliguria, pulmonary edema, neurologic symptoms, persistent epigastric or right upper quadrant pain, hepatocellular injury, thrombocytopenia, or fetal growth restriction. Liver involvement happens in ten to twenty percent of preeclamptic pregnancies.

8:37HELLP is the severe end of the same vascular pathology. The acronym names the lab triad. Hemolysis with LDH at or above six hundred. Elevated liver enzymes with AST at or above seventy. Low platelets at or below one hundred thousand. Those are the Tennessee criteria. The Tennessee classification then stratifies severity by platelet count. Class one is platelets below fifty thousand and carries the highest maternal mortality. Class two is fifty to one hundred thousand. Class three is one hundred to one hundred fifty thousand, with the most preserved hemostasis. The classes correlate directly with bleeding risk at delivery and with how aggressively you transfuse platelets. HELLP affects zero point one to zero point six percent of pregnancies. It develops before delivery in seventy percent of cases and after delivery in thirty percent, within two weeks postpartum. And twenty percent of HELLP cases occur without hypertension, which is the part that catches the diagnosis off-guard.

9:35The shared mechanism of preeclampsia and HELLP is vascular. Placental endothelial dysfunction releases antiangiogenic factors, sFlt-1 and soluble endoglin, that produce maternal endothelial injury, vasoconstriction, and microvascular fibrin deposition. In the liver, fibrin thrombi in hepatic sinusoids produce sinusoidal obstruction and periportal hepatocyte ischemic necrosis with periportal hemorrhage on histology. The hemolysis in HELLP is microangiopathic. Red cells fragment physically against fibrin strands in injured small vessels, which is why you see schistocytes, low haptoglobin, and elevated LDH. Liver enzymes can reach the thousands. Bilirubin usually stays below five and is mostly unconjugated from the hemolysis. Maternal mortality in HELLP is one to three and a half percent. Perinatal mortality runs fifty-six to three hundred sixty-seven per thousand live births. The disease can worsen in the first forty-eight hours after delivery before it improves, which is a counterintuitive piece of the post-delivery course worth holding onto.

10:41Treatment of preeclampsia and HELLP is delivery as the definitive intervention. The reason is that the placental endothelial dysfunction does not resolve until the placenta is gone. You can manage the consequences with ICU monitoring, blood pressure control, magnesium sulfate for seizure prophylaxis, and antenatal corticosteroids for fetal lung maturity if delivery is less than thirty-two weeks. Platelet transfusion to above forty thousand at delivery or for procedures is part of the supportive package. But none of those treat the disease. Only placental removal does. Recurrence in subsequent pregnancies is approximately seven percent.

11:19AFLP is the other third-trimester emergency, rarer, with a different mechanism, and the high-yield board distinction. Roughly one in six thousand six hundred to twenty thousand pregnancies. Mean presentation at thirty-six weeks. Risk factors include multigravida status, twin pregnancies, coexisting liver diseases of pregnancy, and male fetal sex. The presentation is rapid-onset jaundice, coagulopathy, hypoglycemia, and lactic acidosis.

11:47The mechanism is testable directly, and it is what separates AFLP from HELLP. AFLP is driven by fetal long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency, LCHAD. The mother is heterozygous for the LCHAD mutation. The fetus is homozygous. Defective fetal beta-oxidation of long-chain fatty acids spills unmetabolized long-chain fatty acids into the maternal circulation, where the maternal hepatic mitochondrial fatty acid oxidation pathway becomes overwhelmed. The result is microvesicular steatosis, predominantly in zone three of the liver, with non-membrane-bound triglyceride and free fatty acid droplets, and hepatic architecture is otherwise preserved with subtle or absent inflammation. The mitochondrial dysfunction explains everything you see clinically. Impaired gluconeogenesis produces hypoglycemia. Impaired hepatic synthesis produces coagulopathy. Ammonia accumulates and produces encephalopathy. Impaired pyruvate metabolism produces lactic acidosis. The phenotype is a mitochondrial fatty acid oxidation crisis in the maternal liver, triggered by a fetal genetic defect.

12:58The Swansea criteria establish the diagnosis when six or more features are present in the absence of another explanation. Vomiting. Abdominal pain. Polydipsia or polyuria. Elevated transaminases. Elevated bilirubin. Renal impairment. Encephalopathy. Hypoglycemia. Coagulopathy. Ascites or bright liver on ultrasound. Microvesicular steatosis on biopsy. Leukocytosis. Elevated urate. The positive predictive value is about eighty-five percent. The negative predictive value approaches one hundred percent. That is why biopsy is rarely necessary.

13:35Distinguishing AFLP from HELLP is the high-yield board distinction, and it follows directly from the mechanism. AFLP-specific features are hypoglycemia, encephalopathy, coagulopathy, polydipsia or polyuria, microvesicular steatosis, elevated urate, and marked leukocytosis often above fifteen thousand. The AST-to-ALT ratio in AFLP runs above one. HELLP-specific features are microangiopathic hemolysis with schistocytes, markedly elevated LDH, and deep thrombocytopenia. Both can present with vomiting, right upper quadrant pain, transaminase elevation, bilirubin elevation, and renal impairment, which is why the overlap traps the diagnosis. About half of AFLP cases also have features of preeclampsia, which is the other reason the discrimination matters. The way to keep the distinction straight is to remember what each disease is mechanistically. HELLP is a microvascular fibrin-and-shear problem. So you look for evidence of shear: schistocytes, hemolysis markers, deep thrombocytopenia from consumption. AFLP is a mitochondrial fatty acid oxidation problem. So you look for evidence of mitochondrial dysfunction: hypoglycemia, hyperammonemic encephalopathy, coagulopathy from synthetic failure, lactic acidosis.

14:58Management is delivery as the only definitive treatment, ICU supportive care, imaging to exclude hepatic hemorrhage or rupture, and liver transplantation for worsening liver failure, which requires transfer to a transplant center. Both mother and infant undergo genetic testing for LCHAD deficiency. Infants with confirmed deficiency develop nonketotic hypoglycemic coma with stress or fasting, which is reversible with adequate feeding once recognized. Historical maternal mortality without prompt delivery was seventy to eighty percent. Modern mortality with timely delivery and supportive care is ten to thirty-three percent. That order-of-magnitude reduction with delivery is the empirical foundation for treating AFLP recognition as a delivery emergency rather than a medical disease. Fetal and perinatal mortality remains substantial, on the order of fifteen to twenty-five percent in contemporary series, and higher, up to roughly sixty percent, in the subset with LCHAD-deficient fetuses.

15:59Then there is the catastrophic complication that sits inside this spectrum. Hepatic infarction with subcapsular hematoma or capsular rupture. It is rare, occurring in roughly one to two percent of HELLP and severe preeclampsia pregnancies. Hepatic hematoma is reported in a larger minority of HELLP patients, but progression to capsular rupture stays in the one to two percent range. AFLP can also produce it, less commonly. The presentation is sudden severe abdominal pain, often radiating to the right shoulder or scapula from diaphragmatic irritation. That referred pain is the pregnancy analog of Kehr sign. Transaminases often crash through three thousand to six thousand units per liter. Spiking fevers. Anemia from blood loss into the subcapsular space. CT or MRI shows predominantly right-lobe involvement.

16:48The decision tree depends on hemodynamics. A hemodynamically unstable patient with active bleeding gets aggressive resuscitation with blood products and either surgical intervention or hepatic artery embolization by interventional radiology. Maternal mortality in that scenario runs fifty-six to seventy-five percent. Fetal mortality runs sixty-two to seventy-seven percent. A hemodynamically stable patient with a contained subcapsular hematoma is managed conservatively with correction of coagulopathy and serial imaging.

17:18It helps to keep a differential by trimester as a recognition guide. First trimester through twenty weeks, hyperemesis gravidarum. Second to third trimester, intrahepatic cholestasis of pregnancy. Third trimester after twenty weeks, preeclampsia. Third trimester after twenty-two weeks, HELLP. Third trimester after twenty-eight weeks, AFLP. Jaundice in the third trimester is concerning regardless of position within that window, and it prompts parallel evaluation for ICP, preeclampsia or HELLP, AFLP, and viral hepatitis.

17:53Pull the pregnancy-specific half together. These syndromes exist only because pregnancy is occurring, and delivery is the definitive treatment for all but ICP. Intrahepatic cholestasis sits on a stillbirth-risk curve that inflects sharply at total bile acids of one hundred, and ursodeoxycholic acid plus bile-acid-stratified delivery timing is the answer, with the normal GGT the discriminator from obstructive cholestasis. The preeclampsia, HELLP, and AFLP spectrum runs on two mechanisms, vascular fibrin-and-shear for preeclampsia and HELLP, and fetal LCHAD-driven mitochondrial overwhelm for AFLP, and you tell them apart by looking for shear versus mitochondrial failure. And hepatic capsular rupture is the catastrophic complication that hemodynamic status triages.

18:40The next episode takes the incidental half of the chapter, the hepatic disease that is not caused by pregnancy but is reshaped by it: viral hepatitis with its virus-specific transmission and antiviral decisions, and pre-existing liver disease where the rule is continue what works and swap out the teratogens.

18:58For the full chapter, the practice vignettes, and the topic-tagged question bank, head to board pearls dot com. You'll find the rest of the series on Apple Podcasts, Spotify, or wherever you listen to podcasts. That brings us to the end of episode three of six of chapter thirty five, and I'll see you in the next one.